New drug cocktail shows promise for tough colon cancer

NCT ID NCT03446157

Completed Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of two drugs, palbociclib and cetuximab, in 24 people with a specific type of advanced colon cancer that had spread. The goal was to see if the combo could shrink tumors or stop them from growing. Participants took palbociclib pills and received cetuximab infusions over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palbociclib and cetuximab
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific genetic type of advanced colon cancer.
What could go wrong: This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The combination may cause side effects and may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE COLON are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer malignant colon neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF THE COLON COLON CANCER COLON NEOPLASMS COLONIC CANCER NEOPLASMS, COLONIC

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, 27599-7295, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.